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Introduction: One of the most dangerous brain tumors is Glioblastoma multiforme 
(GBM).The MMPs are very important biomarker in pathologic conditions and be 
known as metastatic factor. Temozolomide is an oral alkylating agent, and has a 
good effect on GBM. Gefitinib is a low–molecular weight tyrosine kinase inhibitor 
that is used in tratmeant of tumor. 
Methods and Results: The human GBM cell line, U87 mg was obtained from 
Pasteur Institute of Iran. Cells grown in RPMI 1640 supplemented with 10% fetal 
bovine serum in a humidified incubator at 37
0C
 with 5% CO2. Cell viability after 
treatment, was measured by MTT test. MMP-2, MMP-9, Quantikine
®
 ELISA kits 
(R&D systems, Minneapolis, USA) were used to measure supernatants MMPs. 
Effect of the drugs on the enzyme  activity of MMP-2 and MMP-9 was assessed by 
gelatin zymography. Synergism of Temozolomide and Imatinib can reduce the IC50 
of temozolomide. Our results show that combination of Imatinib and Temozolomide 
decreased the level and activity of MMP-2 and MMP-9 in supernatant of culture 
medium versus to control cells when only Temozolomide or Imatinib was added to 
their culture medium. 
Conclusion: Combination of Imatinib as a tyrosine kinase inhibitor and 
Temozolomide as an alkylating agent is more potent than Temozolomide and it can 
reduce IC50 and decrease level and activitity of MMP-2 and MMP-9.The current 
strategies for treatment of glioblastoma are not beneficial enough. Combination 
therapy probably can reduce the dose of drug, cost of treatment, adverse effects and 
increase the survival rate of life. 
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